Key Findings From Recent Trials

Basic Chloroquine Information

• INN (International Nonproprietary Name): Chloroquine
• Brand Names Available In United Kingdom: not specified
• ATC Code: P01BA01 — Chloroquine (antimalarial agent); classified under P01B Antimalarials, P01 Antiprotozoals, P Antiparasitic products
• Forms & Dosages: Tablets 100 mg, 150 mg, 250 mg, 500 mg; Syrup/Solution 50 mg/5 ml (paediatric); Injectable forms 150 mg base/ml (limited use)
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription Only (Rx)

Are recent high-quality trials still changing how clinicians view chloroquine?

Major randomised controlled trials between 2022 and 2025 continued to show no clinical benefit for chloroquine in COVID-19 treatment or prevention.

These chloroquine COVID RCTs confirmed an absence of efficacy and reinforced earlier findings from the pandemic era.

Large pharmacovigilance reviews since 2020 highlighted persistent safety concerns that limit off‑label use.

Malaria surveillance between 2022 and 2025 showed geographic heterogeneity in Plasmodium falciparum resistance.

Chloroquine retains activity only in limited P. vivax and historical settings where resistance has not emerged.

Regulatory re‑evaluations in the post‑COVID era have narrowed recommended indications to antimalarial use where susceptibility exists and specified rheumatologic regimens.

The ATC classification P01BA01 aligns chloroquine with antiprotozoal and antimalarial agents in clinical practice.

Major suppliers named internationally include Sanofi (Nivaquine) and generic manufacturers such as Ipca and Emzor.

UK relevance: chloroquine is recorded as Prescription Only and off‑label COVID use is discouraged by major agencies.

Major 2022–2025 Studies

Which trials mattered most for clinicians and pharmacists?

Randomised controlled trials in hospital and community settings continued to examine chloroquine versus standard care for viral illness; none showed meaningful clinical improvement.

Large observational pharmacovigilance datasets flagged dose‑related cardiac and retinal events in real‑world populations.

Malaria surveillance studies used therapeutic efficacy monitoring to map chloroquine resistance trends across endemic regions.

These studies underpin current treatment guidelines that favour artemisinin‑based combinations for most P. falciparum infections.

Main Outcomes

What were the central takeaways from these trials?

There was no convincing antiviral benefit from chloroquine for COVID-19 in recent RCTs, and no change to its antimalarial role in susceptible areas.

Therapeutic failure against P. falciparum remains common in many regions, limiting chloroquine to specific P. vivax or historically susceptible zones.

For autoimmune disease, controlled data support immunomodulatory benefit but hydroxychloroquine is usually preferred for safety reasons.

Safety Observations

What safety signals should prescribers heed?

Cardiotoxicity with QT prolongation and potentially fatal arrhythmias is the clearest short‑term hazard, especially with interacting drugs.

Long‑term use shows dose‑related retinopathy risk and, rarely, cardiomyopathy with cumulative exposure.

Pharmacovigilance reviews also noted common mild adverse effects such as nausea, headache and pruritus in real‑world cohorts.

Clinical Mechanism Of Action

Layman’s Explanation

How does chloroquine work in simple terms?

Chloroquine collects inside acidic compartments of both parasite and human cells and raises the internal pH.

This change prevents the malaria parasite from safely disposing of toxic haem, which then builds up and kills the parasite.

The drug also alters immune signalling in a way that can calm inflammatory conditions like lupus or rheumatoid arthritis.

Scientific Breakdown

What is the biochemical basis clinicians need to know?

Chloroquine is a weak base that concentrates in lysosomes and the Plasmodium food vacuole, raising pH and inhibiting haemozoin formation.

The resulting accumulation of toxic free haem damages parasite membranes and disrupts metabolism.

Parasite resistance develops through efflux transporters and vacuolar pH adaptations that reduce intravacuolar drug concentrations.

Parasite‑Targeted Actions

Which parasite processes are targeted?

Inhibition of haemozoin crystallisation is the primary antimalarial mechanism, impairing the parasite’s use of host haemoglobin.

That makes chloroquine effective where parasites have not evolved resistance mechanisms to remove or neutralise the drug.

Immunomodulatory Effects

How does chloroquine affect the immune system?

The drug interferes with endosomal Toll‑like receptor signalling and autophagy pathways, reducing activation of certain inflammatory cascades.

These immunomodulatory properties explain its off‑label and rheumatologic uses, though hydroxychloroquine is often preferred for safety.

Pharmacokinetics include a long half‑life and tissue accumulation in retina and myocardium, which explains both durable effect and cumulative toxicity risk.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

What is chloroquine officially approved for?

Raw registration data show chloroquine remains registered for antimalarial indications in many endemic countries and for certain rheumatologic uses broadly.

The specific list of brand licences and registration status in the United Kingdom is not specified in the available data.

Clinicians in the UK commonly use hydroxychloroquine in rheumatology because it generally has a more favourable safety profile.

Notable Off‑Label Trends

Which off‑label uses have been most visible recently?

The highest‑profile off‑label use was during the COVID‑19 pandemic, but major regulatory agencies revoked emergency use due to lack of efficacy and safety concerns.

Other less common off‑label uses include targeted treatment for amebiasis in specific clinical settings.

Internationally available brands include Aralen, Nivaquine, Lariago, Emquin and Emzor, but local availability and formulation licensing vary by country.

Dosage Strategy

General Dosing

How should pharmacists calculate chloroquine doses?

Always use weight‑based dosing for children and ensure adult doses are calculated as mg base, not salt, to avoid errors.

Tablets commonly come in 100 mg, 150 mg, 250 mg and 500 mg strengths, and paediatric syrup is typically 50 mg/5 ml.

Adjust doses downwards in liver or kidney impairment and in older patients due to accumulation risk.

Condition‑Specific Dosing

What are the standard regimens for key indications?

Acute malaria adult regimen: 600 mg base initially, then 300 mg base at 6, 24 and 48 hours (total 1.5 g base).

Paediatric malaria dosing: 10 mg/kg base initially, then 5 mg/kg base at 6, 24 and 48 hours.

Rheumatologic maintenance is typically 250–500 mg daily, with monitoring of cumulative exposure and regular ophthalmology checks.

Amebiasis regimens often start 600 mg base daily for 2 days followed by 300 mg for 2–3 weeks under supervision.

For all uses, convert between salt and base when documenting doses and make the mg base explicit on prescriptions.

Safety Protocols

Contraindications

Who must not take chloroquine?

Absolute contraindications include known hypersensitivity to chloroquine or related compounds, pre‑existing retinal or visual field changes, and a history of epilepsy.

Relative contraindications that need enhanced monitoring include liver disease, renal impairment, psoriasis, porphyria, myasthenia gravis and alcoholism.

Concomitant use with QT‑prolonging agents is also a relative contraindication requiring risk assessment.

Adverse Effects

What adverse effects should patients expect and how are they monitored?

Common mild effects include nausea, headache and pruritus, with the latter more frequently reported in African populations.

Moderate effects can include blurred vision, skin rash and mood changes.

Critical long‑term risks are dose‑related retinopathy and cardiomyopathy, and acute cardiotoxicity can present as QT prolongation and arrhythmias.

Monitoring protocol should include baseline ophthalmology and periodic retinal screening for long courses, and baseline ECG and electrolytes for patients with cardiac risk.

Document informed consent for long‑term therapy and provide clear overdose instructions: chloroquine overdose is life‑threatening and needs emergency care.

Interaction Mapping

Food Interactions

Does food change chloroquine absorption?

Food interactions are limited, but antacids and polyvalent cations can alter absorption; advise consistent administration relative to meals.

Keeping timing consistent helps with adherence and predictable plasma levels for chloroquine tablets or syrup.

Drug Combinations To Avoid

Which drug combinations raise safety concerns?

Avoid or closely monitor combinations with other QT‑prolonging agents such as macrolides, certain antipsychotics and fluoroquinolones.

Class Ia and III antiarrhythmics and drugs that lower seizure threshold also increase risk and require careful review.

CYP inhibitors or inducers can alter chloroquine exposure, and electrolyte disturbances (hypokalaemia, hypomagnesaemia) amplify QT risk.

When polypharmacy raises interaction risk in rheumatology, consider hydroxychloroquine as an alternative with a more favourable interaction profile.

Patient Experience Analysis

Survey Data

What do patients report about using chloroquine?

Surveys and patient‑reported outcomes commonly cite tolerability issues such as gastrointestinal upset, headaches and itching.

Long‑term users express concern about visual changes and anxiety over cumulative retinal toxicity.

Adherence is affected by the need for monitoring appointments and publicity around cardiac risks from the COVID‑era discussions.

Forum Trends

What do online forums reveal?

Social media and forum analysis show persistent confusion over off‑label COVID claims and brand names such as Aralen, Nivaquine and Avloclor.

Access issues are reported in non‑endemic areas where chloroquine is less stocked, and paediatric syrup can be difficult to obtain.

Clear clinician communication about expected side effects, monitoring timelines and storage instructions improves patient confidence and adherence.

Distribution And Pricing Landscape

Global Suppliers And Packaging

Who supplies chloroquine and how is it packaged?

International suppliers named in available data include Sanofi (Nivaquine), Ipca Laboratories and larger manufacturers such as Bayer and Novartis.

Local manufacturers listed include Emzor (Nigeria), Medreich (India) and EMS (Brazil).

Packaging formats globally are tablets (100–500 mg), paediatric syrup (50 mg/5 ml) and limited injectable forms (150 mg base/ml).

Generic competition typically keeps unit prices low in endemic markets but availability varies by country and formulation.

Market Trends In The United Kingdom

How does the UK market compare?

Demand in the UK is modest because hydroxychloroquine is preferred for rheumatology and artemisinin combinations are favoured for falciparum malaria.

Stock fluctuations during the COVID‑19 pandemic showed vulnerability to sudden demand spikes and regulatory constraints.

Procurement guidance for NHS trusts includes verifying GMP certification for suppliers and checking national drug registers for licencing.

In our online pharmacy, chloroquine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Which drugs are reasonable alternatives to chloroquine?

Hydroxychloroquine shares a similar mechanism and is generally preferred in rheumatology for a better safety profile and lower retinopathy risk at standard doses.

Artemisinin‑based combination therapies (ACTs) are first‑line for P. falciparum in most endemic settings due to superior efficacy against resistant strains.

Mefloquine can work in some resistant malaria but is limited by neuropsychiatric adverse effects.

Primaquine is used for radical cure of P. vivax hypnozoites and requires G6PD testing before use.

Pros And Cons

How should clinicians choose between agents?

Chloroquine advantages include low cost and simple oral dosing where parasites are susceptible.

Disadvantages include widespread P. falciparum resistance, cumulative toxicity and multiple contraindications.

Select therapy based on species identification, local susceptibility patterns, patient comorbidities and the safety profile of each agent.

Regulatory Status

International Registrations

Where is chloroquine currently registered?

Chloroquine remains registered for antimalarial use in many malaria‑endemic countries and appears on the WHO Model List of Essential Medicines.

Historic approvals exist in the EU and USA, but many regulators updated authorised indications after pandemic‑era reviews.

Registration details differ by country and brand, so always check national drug registries before procurement.

UK Regulatory Considerations

What should UK prescribers watch for?

Specific registration status in the United Kingdom is not specified in the available dataset, but most countries classify chloroquine as Prescription Only.

Regulatory imperatives include label‑mandated ophthalmologic monitoring for prolonged therapy and contraindications related to retinal disease and epilepsy.

Prescribers should align practice with MHRA guidance and local formularies when selecting antimalarials and rheumatologic agents.

Consolidated FAQ

Rapid Q&A For Clinicians And Patients

Is chloroquine prescription‑only in the UK?

Available data state that chloroquine is classified as Prescription Only (Rx) in nearly all countries.

What is the adult dose for acute malaria?

Adult regimen: 600 mg base initially, then 300 mg base at 6, 24 and 48 hours (total 1.5 g base).

What monitoring is required for long‑term therapy?

Baseline ophthalmology with periodic retinal exams, and ECG if cardiac risk or when combined with QT‑prolonging drugs.

Can chloroquine be used for COVID‑19?

No; recent high‑quality trials and regulatory reviews do not support its use for COVID‑19 outside clinical trials.

What are the most common side effects?

Mild: nausea, headache, pruritus (noted especially in some African populations).

Serious long‑term risks: retinopathy and cardiomyopathy.

How should it be stored?

Store at room temperature 15–25°C, protected from light and moisture, and keep out of reach of children.

What to do in overdose?

Chloroquine overdose is life‑threatening with cardiac arrhythmia and convulsions; seek emergency care immediately.

Visual Guide

Recommended Diagrams

Which visuals help clinicians and patients most?

Include a dosing flowchart showing adult and paediatric weight‑based pathways for acute malaria and maintenance dosing for rheumatologic conditions.

Add a mechanism schematic showing food vacuole pH change, haemozoin inhibition and immune modulation.

Provide a monitoring timeline infographic with baseline ECG, ophthalmology baseline and intervals, and liver/renal checks.

Create an interaction map that visually links chloroquine with high‑risk QT drugs to aid rapid decision making.

Clinician Checklists

What quick checks should prescribers use?

Checklist items: confirm indication and species susceptibility, obtain baseline investigations, reconcile medications for QT interactions and document informed consent for long‑term therapy.

Visuals of common formulations (tablets 100–500 mg; syrup 50 mg/5 ml; injectable 150 mg base/ml) reduce dosing errors in practice.

Storage And Transport

Practical Handling And Supply Chain Notes

How should chloroquine be stored and transported?

Store at controlled room temperature 15–25°C, protected from light and moisture, and keep away from children.

During transport, avoid prolonged exposure to heat or freezing and protect blister packs or bottles from humidity.

Paediatric syrup must have tamper‑evident packaging and be used within the manufacturer‑stated shelf life once opened.

For hospital stocks, label shelves with formulation strengths to prevent dispensing errors and verify GMP certification from suppliers during procurement.

Maintain records per NHS pharmacy policy and have local poison centre contact details readily available for suspected overdose.

Guidelines For Proper Use

Clinical Prescribing Checklist

What steps reduce risk when prescribing chloroquine?

Confirm the indication and, for malaria, the species and local susceptibility before selecting chloroquine.

Perform baseline screening including ECG, ophthalmology and LFTs/renal function where indicated and reconcile all medications for QT interactions.

Use weight‑based paediatric dosing and convert salt to base as required; document mg base on the prescription.

Patient Instructions

What should patients be told when they receive chloroquine?

Advise taking the medicine consistently with regard to meals and to report any visual changes or palpitations immediately.

Explain not to double up if a dose is missed and to store medication at 15–25°C away from children.

For long‑term therapy, provide a monitoring timetable for ophthalmology and ECGs and obtain documented informed consent about retinal and cardiac risks.

Avoid prescribing chloroquine for COVID‑19 outside clinical trials and consult infectious disease or rheumatology specialists for complex cases.

Delivery Across United Kingdom